← Back to all trials
Terminated
NCT02415062
The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia
Conditions: Parkinson's Disease
Sex: All
Ages: 50 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 10
Sponsor: Inje University
Location: Inje university, busan paik hospital Busan
Summary
The purpose of this study to evaluate the safety and efficacy of high-dose donepezil (23mg) in Parkinson's disease with dementia compared to standard dose donepezil.
Eligibility Criteria
Inclusion criteria :
* Patients diagnosed as Parkinson's disease according to Queen Brain Bank criteria
* Patients who have been diagnosed as dementia after diagnosing Parkinson's disease at least 1 year.
* Patients with Hoehn and Yahr staging from 2 to 4
* Patients with MMSE score from 10 to 24
* Patients who have taken donepezil for at least 12 weeks before screening period
* Patients whose medications for Parkinson's disease have not change for 1 month
* Patients who give informed consent
Exclusion criteria :
* Patients who cannot be performed neuropsychiatric test because of hearing and visual difficulty
* Patients who have taken medicine affecting cognitive function such as anticholinergic drug and memantine -Patients diagnosed as dementia with Lewy body and vascular dementia-
* Patients who have history of neurosyphilis, head trauma, encephalitis or other movement disorders
* Patients who have psychiatric disease
* Except patients who are stable state under antidepressant or atypical neuroleptics
* Patients with child-bearing periods
* Patients who have severe liver or kidney disease necessary for aggressive treatment
* Patients who have gastrointestinal disease needed for treatment
* Patients who cannot taken tablet per oral
* Patients who are participated in other clinical trial except observational study
Source: ClinicalTrials.gov (NCT02415062). StuddyBuddy aggregates publicly available trial information.